Skip to main content
. Author manuscript; available in PMC: 2016 Apr 29.
Published in final edited form as: J Am Geriatr Soc. 2015 Feb 2;63(2):365–370. doi: 10.1111/jgs.13192

Table 4.

Screening Prevalence at Baseline and at the End of the Study for the Experimental and Control Groups (N = 488)

Screening Experimental, n = 242
(n = 128 Women; n = 114
Men)		 Control, n = 246
(n = 132 Women;
n = 114 Men)		 Chi-Square
(Degrees of
Freedom),
P-Value (Exit)
Baseline Exit Baseline Exit
n (%)
Fecal occult blood test within past 12 months 31 (12.8) 50 (20.7) 27 (11.0) 31 (12.6) 5.16 (1), .02
Endoscopy within past 5 years 60 (24.8) 104 (43.0) 62 (25.2) 67 (27.2) 12.59 (1), <.001
Papanicolaou test within past 24 months 48 (37.5) 73 (57.0) 52 (39.4) 48 (36.4) 10.30 (1), .001
Mammogram within past 12 months 38 (29.7) 79 (61.7) 47 (35.6) 56 (42.4) 8.93 (1), .003
Prostate-specific antigen test within past 12 months 22 (19.3) 62 (54.4) 28 (24.6) 41 (36.0) 7.08 (1), .008

The groups did not differ statistically in baseline screening prevalence.